backKing & Spalding advised Oxford Biomedica PLC (LSE: OXB) on its $125,000,000 secured loan facility provided by Oaktree Capital Management. Established in 1995, OXB is a leading global cell and gene therapy contract development and manufacturing organisation, with development and manufacturing facilities in the United Kingdom, France and the United States.
A cross-disciplinary King & Spalding team across London, New York, Singapore and Paris advised OXB in relation to all aspects of the financing package.
The transaction was jointly led by partners Amin Doulai (London), Serena Granger (New York) and Marisa Sotomayor (New York), and included Marcus Young (London), John Sweet (New York), Shelby Epstein (New York), Zarmina Tirmzi (Singapore), Taeyeong Kim (London), Michael Langan (London), Delphine Guillotte (Paris), Fernand Arsanios (Paris), Guillaume Chaboureau (Paris), Houda Idaroussi (Paris), and Alexandre Chagneau (Paris), with paralegal support by Alanna Quinn (Atlanta).